Palsonify (paltusotine)
- Region
- 🇪🇺 EU
- Active substance
- paltusotine
- Company
- Crinetics Pharmaceuticals Europe GmbH
- Status
- Authorised
- Therapeutic area
- Acromegaly
- CHMP opinion
- Thu 26 Feb 2026
- EU approval
- Thu 23 Apr 2026
- Designations
- Orphan, Additional monitoring
- Application
- EMEA/H/C/006636
- ATC
- H01CB06
- Official record
- www.ema.europa.eu
Indication
Palsonify is indicated for the medical treatment of adult patients with acromegaly.
Regulatory milestones
Palsonify (paltusotine) approved in the EU
Marketing authorisation to Crinetics Pharmaceuticals Europe GmbH; Orphan, Additional monitoring · source
Palsonify (paltusotine): CHMP positive opinion
Crinetics Pharmaceuticals Europe GmbH; Orphan, Additional monitoring · source
PALSONIFY: PDUFA target action date (acromegaly)
Crinetics Pharmaceuticals, Inc. (CRNX); paltusotine; NDA; status: set; "Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Regulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY™ (paltusotine) New Drug Application with September 25, 2025 PDUFA Date Continued Progress on the Global Development…"; filed 2025-08-07 · source
Same substance in other markets
- 🇺🇸 Palsonify Approved · Crinetics
Follow Palsonify
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.